Leash Biosciences, a biotech company based in Salt Lake City, UT, has secured $9.3M in Seed funding.

The funding round was led by Springtide Ventures with contributions from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, as well as Recursion co-founders Chris Gibson and Blake Borgeson.

The funds will be channeled into developing a machine learning model to predict small molecule drug candidates for various protein targets.

Led by CEO Ian Quigley, Leash Biosciences leverages AI/ML to accelerate the creation of novel therapeutics. With new headquarters in Salt Lake City, Leash aims to screen over 500 protein targets using proprietary chemicals by 2025.